Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions.

about

Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions.

Item

http://www.wikidata.org/entity/Q38653626

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Targeted Therapies for Advance ...... rogress and Future Directions.

@en

type

Item

label

Targeted Therapies for Advance ...... rogress and Future Directions.

@en

prefLabel

Targeted Therapies for Advance ...... rogress and Future Directions.

@en

P1476

Targeted Therapies for Advance ...... rogress and Future Directions.

@en

P2093

Ian Chau

http://www.w3.org/2001/XMLSchema#string

Kate Young

http://www.w3.org/2001/XMLSchema#string

P2860

Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum

Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Comprehensive molecular characterization of gastric adenocarcinoma

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

P2888

s40265-015-0510-y

P304

13-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-015-0510-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1010598976

http://www.w3.org/2001/XMLSchema#string

P698

26620367

http://www.w3.org/2001/XMLSchema#string